COMP <GO>
ZLAB vs NAMS // PIOTROSKI F-SCORE QUALITY
Zai Lab Limited (NASDAQ) VS. NewAmsterdam Pharma Company N.V. (NASDAQ) • 15-METRIC TALLY: ZLAB 5
— NAMS 3
▲ PIOTROSKI F-SCORE QUALITY LEADER: ZLAB
LAST: $22.36 (-2.95%) • MKT CAP: $2.51B
piotroski-score
5/9
LAST: $20.76 (-1.47%) • MKT CAP: $2.48B
piotroski-score
3/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ZLAB VS. NAMS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ZLAB | NAMS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 58.30% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.33% | -5.96% | -0.37 | NAMS | /fcf-yield <GO> |
| Operating Margin | -50.20% | -60.00% | +9.80 | ZLAB | /operating-margins <GO> |
| Net Profit Margin | -38.40% | -60.00% | +21.60 | ZLAB | /net-margins <GO> |
| Revenue Growth (YoY) | 15.00% | -50.60% | +65.60 | ZLAB | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.52 | 15.94 | -15.42 | NAMS | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 5/9 | 3/9 | +2.00 | ZLAB | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.3 | 40.7 | -0.41 | NAMS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.51B | $2.48B | $28.7M | ZLAB | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ZLAB REV | NAMS REV | ZLAB GROSS % | NAMS GROSS % | ZLAB FCF | NAMS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $457.2M | $22.5M | 58.3% | — | -$158.9M | -$147.8M |
| FY 2024 | $397.6M | $45.6M | 63.0% | — | -$220.5M | -$158.6M |
| FY 2023 | $266.7M | $14.1M | — | — | -$198.2M | -$141.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ZLAB // BETA —
NAMS // BETA —